Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States. The company is headquartered in Cambridge, Massachusetts.
| Revenue (TTM) | $156.03M |
| Gross Profit (TTM) | $-252.63M |
| EBITDA | $-355.78M |
| Operating Margin | -25827.00% |
| Return on Equity | -8.18% |
| Return on Assets | -17.00% |
| Revenue/Share (TTM) | $1.51 |
| Book Value | $10.69 |
| Price-to-Book | 2.59 |
| Price-to-Sales (TTM) | 17.71 |
| EV/Revenue | 11.9 |
| EV/EBITDA | -7.03 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -94.20% |
| Shares Outstanding | $103.29M |
| Float | $88.34M |
| % Insiders | 1.37% |
| % Institutions | 107.92% |
Volatility is currently contracting
Beam Therapeutics posts a wider-than-expected Q2 loss. Revenues also miss estimates as it advances multiple genome-editing programs with key clinical milestones ahead.
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.18 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to a loss of $1 per share a year ago.
Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026
Beam Therapeutics offers compelling upside, with a $2.64B market cap and a promising gene-editing pipeline spanning hematology and liver-targeted diseases. Lead programs Risto-cel, BEAM-302, and BEAM-301 demonstrate superior or competitive efficacy and safety profiles versus key competitors, supporting significant commercial potential. BEAM's $1.2B liquidity provides a cash runway well into 2029, with additional revenue from collaborations, notably with Eli Lilly and Pfizer.
CAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated clinical data from the Phase 1/2 trial evaluating BEAM-302 for alpha-1 antitrypsin deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026, taking place September 5–9, 2026, in Barcelona, Spain.
Prime Medicine, Inc. secured a favorable arbitration ruling against Beam Therapeutics, allowing continued development of its PM647 gene editing program for AATD. PRME's Prime Editing platform offers precise, versatile gene correction using LNP delivery, but remains preclinical with IND/CTA filings for PM647 expected mid-2026 and initial clinical data in 2027. PRME lags competitors like Beam, Sanofi, and Arrowhead in the AATD development race, facing significant funding needs and clinical risks.
Prime Medicine Inc. (NASDAQ:PRME) said it secured a favorable, binding arbitration ruling in its dispute with Beam Therapeutics Inc. (NASDAQ:BEAM).
Beam Therapeutics gains after the FDA clears the IND for BEAM-304 in PKU, advancing its liver-targeted gene-editing program into clinical testing.
BEAM-304 Development Approach Has Potential to Create Transformative, One-time Therapies for the Majority of Patients with PKU BEAM-304 Program Designed as Platform-based Approach Reflecting Emerging FDA Guidance for Accelerated Development of Genome Editing Therapies New Preclinical Data for BEAM-304 to be Presented at FASEB Genome Engineering: Research and Applications Conference CAMBRIDGE, Mass., June 18, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for BEAM-304 for the treatment of phenylketonuria (PKU).
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BEAM and any ticker you trade — then tracks every position and per-strategy win rate.
